SCHEMBL17593204

SCHEMBL17593204

CC(C)(C)OC(=O)N1[C@@H]2CCC[C@H]1C[C@@H](N)C2

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.63
CHRM1 P11229 1/20 0.63
CHRM3 P20309 1/20 0.63
PREP P48147 4/20 0.49
KAT2B Q92831 1/20 0.42
HSD11B1 P28845 1/20 0.39
HPGD P15428 1/20 0.39
EIF2AK4 Q9P2K8 1/20 0.37
EPHX1 P07099 1/20 0.37
NR1H2 P55055 1/20 0.36
GPR119 Q8TDV5 2/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
BTK Q06187 1/20 0.36
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8185274 1.00 CHRM2 (0.63) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL28411457 1.00 CHRM2 (0.63) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL22054254 1.00 CHRM2 (0.63) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL19728174 1.00 CHRM2 (0.63) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL19728173 1.00 CHRM2 (0.63) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL25888649 1.00 CHRM2 (0.63) CHRM2CHRM1CHRM3PREPKAT2B
Oxalic Acid SCHEMBL30147225 0.95 CHRM2 (0.58) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL25247226 0.93 CHRM2 (0.72) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL16192794 0.93 CHRM2 (0.72) CHRM2CHRM1CHRM3PREPKAT2B
SCHEMBL8011988 0.93 CHRM2 (0.72) CHRM2CHRM1CHRM3PREPKAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577363-B2 Substituted piperidine compounds Epizyme, Inc. (US) 2020-03-03 US disclosed
US-20170362217-A1 Substituted Piperidine Compounds Epizyme, Inc. (US) 2017-12-21 US disclosed
EP-3193605-A1 SUBSTITUTED PIPERIDINE COMPOUNDS Epizyme, Inc. (US) 2017-07-26 EP disclosed
WO-2016040515-A1 SUBSTITUTED PIPERIDINE COMPOUNDS Epizyme, Inc. (US) 2016-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10577363-B2 Substituted piperidine compounds SMYD3, SMYD2, SNRPD3 CHRM2 3204/4885CHRM1 3552/4885CHRM3 3863/4885
US-20170362217-A1 Substituted Piperidine Compounds SMYD3, SMYD2, SNRPD3 CHRM2 3204/4885CHRM1 3552/4885CHRM3 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.